M4 leukemia is more serious.
M4 leukemia refers to M4 acute non-lymphoblastic leukemia, i.e., acute granulomonocytic leukemia. Its bone marrow cytology is characterized by abnormally active bone marrow proliferation, with granulocytes and monocytes predominating, while the red lineage and megakaryocytes are suppressed.
1.DA regimen (Zoerythromycin + cytarabine) is usually the first choice for the treatment of acute non-lymphoblastic leukemia, but the complete remission rate of this group of patients after induction chemotherapy is relatively low, and they are prone to relapse after complete remission. Therefore, the prognosis of this type of leukemia patients is poor and the survival time is relatively short, so the condition is very serious.
In the process of chemotherapy, patients will experience bone marrow suppression, and the white blood cell and platelet counts of patients in the period of bone marrow suppression are significantly reduced, and they are prone to infections, bleeding and other serious complications, and in severe cases, the patients’ lives may be jeopardized. Therefore, it is necessary to actively promote hematopoietic recovery after chemotherapy, such as subcutaneous injection of human granulocyte stimulating factor.
2. Allogeneic hematopoietic stem cell transplantation is the fundamental method to treat M4 acute leukemia.
There are individual differences in the conditions of M4 leukemia patients, and they need to consult the hematology department in a timely manner. Specialists have to comprehensively assess the patient’s condition, physical status and prognosis, and then formulate an individualized chemotherapy plan. When complications such as infection and bleeding occur during treatment, it is important to seek timely medical attention.